Literature DB >> 7093527

Fibronectin enhances in vitro monocyte-macrophage-mediated tumoricidal activity.

R T Perri, N E Kay, J McCarthy, R L Vessella, H S Jacob, L T Furcht.   

Abstract

Control of neoplastic proliferation reflects in part monocyte/macrophage destruction of target cells--destruction that evidently requires cell-cell interaction. We herein show it to involve the natural plasma opsonin, fibronectin. With two cultured human tumor lines--Malme melanoma and CAK-I renal carcinoma cells--addition of fibronectin, purified to homogeneity, enhances macrophage-mediated cytotoxicity 2--4-fold (p less than 0.01). Both fresh human monocytes or the U-937-cultured macrophage line become more lethal to tumor cells with added fibronectin. The fibronectin-enhanced monocyte and U-937 tumoricidal activity occurred in a dose-dependent fashion. Specificity of fibronectin's action was validated by use of affinity-purified rabbit antifibronectin antibody, which completely abated its enhancement of tumoricidal activity. Enhancement of tumoricidal activity did not occur when monocytes or U-937 were exposed to fibronectin-coated plates. However, the addition of soluble fibronectin to fibronectin-coated plates was then capable of enhancing cytocidal activity. These studies demonstrate that human fibronectin is capable of increasing both fresh and cultured human monocyte tumor-directed cytotoxicity. Fibronectin appears to be a potentially important circulating molecule that may favorably influence human monocyte tumor cell cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7093527

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Studies on fibronectin in inflammatory vs non-inflammatory polymorphonuclear leucocytes of patients with rheumatoid arthritis. II. Synthesis and release of fibronectin in vitro.

Authors:  C Menard; A D Beaulieu; M Audette; J Corbeil; L Latulippe
Journal:  Clin Exp Immunol       Date:  1985-05       Impact factor: 4.330

2.  Fibronectin plasma levels after cadaver kidney transplantation.

Authors:  R Seitz; M Lutz; R Michalik; H Lange; H G Klingemann; R Egbring
Journal:  Blut       Date:  1985-01

Review 3.  The extracellular matrix modulates the hallmarks of cancer.

Authors:  Michael W Pickup; Janna K Mouw; Valerie M Weaver
Journal:  EMBO Rep       Date:  2014-11-08       Impact factor: 8.807

4.  Comparative analysis of integrin expression on monocyte-derived macrophages and monocyte-derived dendritic cells.

Authors:  C Ammon; S P Meyer; L Schwarzfischer; S W Krause; R Andreesen; M Kreutz
Journal:  Immunology       Date:  2000-07       Impact factor: 7.397

Review 5.  Tumor-associated fibrosis as a regulator of tumor immunity and response to immunotherapy.

Authors:  Hong Jiang; Samarth Hegde; David G DeNardo
Journal:  Cancer Immunol Immunother       Date:  2017-04-27       Impact factor: 6.968

Review 6.  The role of cell adhesion proteins--laminin and fibronectin--in the movement of malignant and metastatic cells.

Authors:  J B McCarthy; M L Basara; S L Palm; D F Sas; L T Furcht
Journal:  Cancer Metastasis Rev       Date:  1985       Impact factor: 9.264

7.  Role of fibronectin in human monocyte and macrophage bactericidal activity.

Authors:  R A Proctor; J A Textor; J M Vann; D F Mosher
Journal:  Infect Immun       Date:  1985-03       Impact factor: 3.441

8.  The distribution of fibronectin in lymph nodes infiltrated by Hodgkin's disease. An immunoperoxidase study on paraffin sections.

Authors:  P Möller; H Achtsätter; M Butzengeiger; B Schüle
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1983

9.  Platelet fibronectin release induced by Walker 256 rat carcinoma tumor cells.

Authors:  W A Turner; D C Szlag; J D Taylor
Journal:  Clin Exp Metastasis       Date:  1985 Jul-Sep       Impact factor: 5.150

10.  Modulation of polyclonal activation by plasma fibronectin and fibronectin fragments.

Authors:  R Dziarski
Journal:  Immunology       Date:  1987-06       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.